Ministry of Health says that they approved to expand the A/H5N1 influenza vaccine clinical trial on human.

          These trials will be conducted on 1.000 healthy volunteers. A/H5N1 influenza vaccine manufactured by The No. 1 Vaccine and Biological production Company has passed the 1 and 2 phase of trial, starting in 2008. Trial results of those phases showed its good effectiveness and safety. With 2 shoots of vaccine, protective effect is over 90%, no adverse reaction.

          H5N1 virus strain has been modified but not significant compared with the strains used to manufacture vaccine. When trials are finished and licensed to use, the vaccine is still capable of protection against A/H5N1 influenza virus which is virulent, high mortality rates.